We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
Read MoreHide Full Article
Key Takeaways
Pfizer's phase III SigVie-002 study missed a statistically significant OS benefit vs docetaxel overall.
Second-line patients, about two-thirds enrolled, showed favorable OS and PFS trends vs docetaxel.
Pfizer is advancing sigvotatug vedotin in NSCLC and other IB6-expressing solid tumor studies.
Pfizer (PFE - Free Report) has announced top-line data from a late-stage study which evaluated its investigational antibody-drug conjugate (ADC), sigvotatug vedotin in previously treated patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).
Sigvotatug vedotin is a potential first-in-class ADC targeting integrin beta-6 (IB6), a protein expressed in about 90% of NSCLC tumors and associated with poor clinical outcomes, making it a compelling therapeutic target.
Year to date, Pfizer’s shares have risen 0.7% compared with the industry’s 1.3% growth.
Image Source: Zacks Investment Research
Key Highlights of PFE’s Phase III SigVie-002 Study for NSCLC
The late-stage SigVie-002 study demonstrated mixed data on the primary endpoint of overall survival (OS). Treatment with sigvotatug vedotin did not demonstrate a statistically significant improvement in OS compared with docetaxel in the overall study population. The safety profile remained consistent with findings from earlier clinical studies. However, patients who had received only one prior line of systemic therapy — representing roughly two-thirds of the enrolled population — showed a more favorable trend in both overall survival and progression-free survival (PFS) compared with docetaxel.
Docetaxel is an FDA-approved chemotherapy drug that has been commonly used as a standard-of-care treatment for many years for the treatment of several cancers, including NSCLC, breast cancer, prostate cancer, gastric cancer and head and neck cancers, particularly in patients whose cancer has progressed after prior therapies.
Despite missing the overall survival endpoint in the broader study population, sigvotatug vedotin demonstrated encouraging survival trends over docetaxel in second-line patients.
PFE’s Other Ongoing Studies on Sigvotatug Vedotin
Beyond the above-mentioned indication, Pfizer continues to advance the clinical development of sigvotatug vedotin through multiple ongoing studies across various stages of NSCLC and other IB6-expressing solid tumors. The key programs include a phase III study evaluating sigvotatug vedotin in combination with Merck’s (MRK - Free Report) Keytruda (pembrolizumab) as a first-line treatment for patients with advanced NSCLC whose tumors have a PD-L1 tumor proportion score of at least 50%. Pfizer is investigating sigvotatug vedotin in novel combination strategies, including with PF-08634404, its investigational bispecific antibody targeting both PD-1 and VEGF, with the aim of enhancing anti-tumor activity in early-stage lung cancer and other IB6-expressing solid tumors.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 15.4% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.
View the Zacks #1 Rank List
Image: Bigstock
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
Key Takeaways
Pfizer (PFE - Free Report) has announced top-line data from a late-stage study which evaluated its investigational antibody-drug conjugate (ADC), sigvotatug vedotin in previously treated patients with advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).
Sigvotatug vedotin is a potential first-in-class ADC targeting integrin beta-6 (IB6), a protein expressed in about 90% of NSCLC tumors and associated with poor clinical outcomes, making it a compelling therapeutic target.
Year to date, Pfizer’s shares have risen 0.7% compared with the industry’s 1.3% growth.
Image Source: Zacks Investment Research
Key Highlights of PFE’s Phase III SigVie-002 Study for NSCLC
The late-stage SigVie-002 study demonstrated mixed data on the primary endpoint of overall survival (OS). Treatment with sigvotatug vedotin did not demonstrate a statistically significant improvement in OS compared with docetaxel in the overall study population. The safety profile remained consistent with findings from earlier clinical studies. However, patients who had received only one prior line of systemic therapy — representing roughly two-thirds of the enrolled population — showed a more favorable trend in both overall survival and progression-free survival (PFS) compared with docetaxel.
Docetaxel is an FDA-approved chemotherapy drug that has been commonly used as a standard-of-care treatment for many years for the treatment of several cancers, including NSCLC, breast cancer, prostate cancer, gastric cancer and head and neck cancers, particularly in patients whose cancer has progressed after prior therapies.
Despite missing the overall survival endpoint in the broader study population, sigvotatug vedotin demonstrated encouraging survival trends over docetaxel in second-line patients.
PFE’s Other Ongoing Studies on Sigvotatug Vedotin
Beyond the above-mentioned indication, Pfizer continues to advance the clinical development of sigvotatug vedotin through multiple ongoing studies across various stages of NSCLC and other IB6-expressing solid tumors. The key programs include a phase III study evaluating sigvotatug vedotin in combination with Merck’s (MRK - Free Report) Keytruda (pembrolizumab) as a first-line treatment for patients with advanced NSCLC whose tumors have a PD-L1 tumor proportion score of at least 50%. Pfizer is investigating sigvotatug vedotin in novel combination strategies, including with PF-08634404, its investigational bispecific antibody targeting both PD-1 and VEGF, with the aim of enhancing anti-tumor activity in early-stage lung cancer and other IB6-expressing solid tumors.
PFE’s Zacks Rank & Stocks to Consider
Pfizer currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 15.4% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.